Combined intravitreal anti-VEGF and verteporfin photodynamic therapy for juxtafoveal and extrafoveal choroidal neovascularization as an alternative to laser photocoagulation

Han, Dennis P.; McAllister, John T.; Weinberg, David V.; Kim, J E; Wirostko, WJ

doi:10.1038/eye.2009.122

Cited by 19 publications

(9 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, Han et al [32] in their retrospective study suggested that anti-VEGF therapy, combined or not with PDT, could be used as an alternative to the ‘gold standard’ laser photocoagulation for non-subfoveal CNV. In our study, comparing the two regimens, i.e.…”

Section: Discussionmentioning

confidence: 99%

Intravitreal Ranibizumab versus Thermal Laser Photocoagulation in the Treatment of Extrafoveal Classic Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Ladas¹,

Chatziralli²,

Kotsolis³

et al. 2012

Ophthalmologica

View full text Add to dashboard Cite

Background: To compare the efficacy of thermal laser photocoagulation versus intravitreal ranibizumab for the treatment of extrafoveal classic choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Methods: We conducted a retrospective study on 24 eyes with extrafoveal classic CNV secondary to AMD, treated either with thermal laser photocoagulation (group 1) or with intravitreal ranibizumab (group 2). Visual acuity, number of injections/sessions and recurrence rate were assessed. Results: The mean follow-up time was 23.6 ± 2.26 and 19.1 ± 9.74 months for group 1 and 2, respectively. Mean best corrected visual acuity (BCVA) of groups 1 and 2 was 0.59 ± 0.32 and 0.46 ± 0.30 logMAR, respectively (p = 0.343). At the end of the follow-up, mean BCVA of group 1 was 0.92 ± 0.35 and of group 2 0.16 ± 0.12 logMAR and differed statistically compared to baseline (p = 0.02 and p = 0.006, respectively). There was a statistically significant difference between the two groups as far as BCVA at the end of the follow-up was concerned (p < 0.0001). The patients in group 1 received on average 1.38 sessions of thermal laser photocoagulation, while patients in group 2 received on average 4 injections of ranibizumab. The recurrence rate in the laser group was 84.6%, while in the ranibizumab group it was 18.2% (p < 0.001). Specifically, the mean time of recurrence in the laser group was 11.5 months, whereas in the ranibizumab group it was 18 months (p = 0.048). Conclusion: Intravitreal ranibizumab showed promising results in BCVA improvement and decrease in macular thickness in patients with extrafoveal classic CNV due to AMD, with a small number of injections. Laser photocoagulation treatment presented worsening in BCVA and high recurrence rate in our study with long-term follow-up.

show abstract

Section: Discussionmentioning

confidence: 99%

Intravitreal Ranibizumab versus Thermal Laser Photocoagulation in the Treatment of Extrafoveal Classic Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Ladas¹,

Chatziralli²,

Kotsolis³

et al. 2012

Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…A randomized head-to-head comparison of ranibizumab and bevacizumab for cases with PM was published by Gharbiya et al [18], presenting no significant differences between the two drugs. Combination therapy of PDT and anti-VEGF was tried by Han et al [19] and did not indicate any advantage over the use of anti-VEGF-therapy alone. Although available data on anti-VEGF treatment of CNV in PM clearly indicates a trend towards favourable functional results with a moderate number of necessary injections, it is hardly possible to conclude on detailed treatment regimens.…”

mentioning

confidence: 99%

Three Years Follow-up Results of Ranibizumab Treatment for Choroidal Neovascularization Secondary to Pathologic Myopia

Hefner

Riese

Gerding

2013

Klin Monatsbl Augenheilkd

View full text Add to dashboard Cite

show abstract

“…A scotoma may be unavoidable as neovascularisation heals with a scar but after the laser treatment, the scotoma may be denser and larger due to the scar enlargement and the photoreceptor damage 4 . Although a new publication showed that anti‐VEGF therapy and photodynamic therapy can preserve good visual function and may be suited to some cases of non‐foveal choroidal neovascularisation, 6 further investigations must be done, comparing the results of extrafoveal choroidal neovascularisation treated with laser photocoagulation and agents for anti‐angiogenesis or photodynamic therapy on the basis of paracentral scotoma.…”

Section: Discussionmentioning

confidence: 99%

Is thermal laser the first but the best choice of treatment for the extrafoveal choroidal neovascularisation?

Aslan¹,

Özdamar²

2010

Clinical and Experimental Optometry

View full text Add to dashboard Cite

Combined intravitreal anti-VEGF and verteporfin photodynamic therapy for juxtafoveal and extrafoveal choroidal neovascularization as an alternative to laser photocoagulation

Cited by 19 publications

References 8 publications

Intravitreal Ranibizumab versus Thermal Laser Photocoagulation in the Treatment of Extrafoveal Classic Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Intravitreal Ranibizumab versus Thermal Laser Photocoagulation in the Treatment of Extrafoveal Classic Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Three Years Follow-up Results of Ranibizumab Treatment for Choroidal Neovascularization Secondary to Pathologic Myopia

Is thermal laser the first but the best choice of treatment for the extrafoveal choroidal neovascularisation?

Contact Info

Product

Resources

About